FDMT - Company ID 0001650648
4D Molecular Therapeutics, Inc. trades as FDMT. In its fiscal 2025 annual report the company posted revenue of $85.21M, up 230194.6% from the prior year and net income of -$140.11M. This page tracks 4D Molecular Therapeutics, Inc. through 387 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 6 fiscal years 4D Molecular Therapeutics, Inc.'s revenue grew from $6.99M to $85.21M, a compound annual growth rate of 51.7%. Net profit margin expanded from -705.8% to -164.4% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| EFFECT | - | 2026-05-13 |
| SCHEDULE 13G | - | 2026-05-12 |
| Securities registration | S-3 | 2026-05-07 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| Annual report to shareholders | ARS | 2026-04-28 |
The largest companies sharing 4D Molecular Therapeutics, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
4D Molecular Therapeutics, Inc. reported revenue of $85.21M for fiscal year 2025, an increase of 230194.6% year over year.
In its latest fiscal year 4D Molecular Therapeutics, Inc. reported a net loss of $140.11M.